[update 10-30-23] Under appreciated in this retrospective study is the fact that the
triple therapy treated arm consisted of risk-stratified elderly and other high-risk patients.While the control group was composed of a broad cross section of
people of all ages and health conditions (so mostly healthy) in the same local, that received various treatments. [end edit]
[update on 1-15-23] Changed title from "Newly Published Outpatient...." to "Peer Reviewed Outpatient....." also "...HCQ+AZ+Z to ".....hydroxychloroquine+Zn+Az....." [end edit]
"UPDATE on 10/29/2020. https://twitter.com/zev_dr
Dr. Zev Zelenko's study has finished the peer review process and has been published in the International Journal of Antimicrobial Agents.Here is a summary of the results from the Abstract:
After 4 days (median, IQR 3-6, available for N=66/141) of onset of symptoms, 141 patients (median age 58 years, IQR 40-67; 73% male) received a prescription for the triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients of the same community were used as untreated control.
4 of 141 treated patients (2.8%) were hospitalized, which was significantly less (p<0.001) compared with 58 of 377 untreated patients (15.4%) (odds ratio 0.16, 95% CI 0.06-0.5).
One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.12). There were no cardiac side effects."
More details from peer reviewed study at the following link:
https://www.sciencedirect.com/science/article/pii/S0924857920304258(pre-print
July 3, 2020 https://www.preprints.org/manuscript/202007.0025/v1 )
end update
_____________________________________
Please disseminate the following article link to Zelenko's protocol far and wide, to everybody on your list and more.
https://www.prnewswire.com/news-releases/newly-published-outpatient-study-finds-that-early-use-of-zinc-hydroxychloroquine-and-azithromycin-is-associated-with-less-hospitalizations-and-death-301094237.htmlHere is the peer reviewed study:
https://www.sciencedirect.com/science/article/pii/S0924857920304258(pre-print
July 3, 2020 https://www.preprints.org/manuscript/202007.0025/v1 )
"Newly Published Outpatient Study Finds that Early Use of Zinc, Hydroxychloroquine and Azithromycin Is Associated with Less Hospitalizations and Death
The study reports a survival rate of over 99% in patients with confirmed positive cases of COVID-19News provided by
Dr. Zev Zelenko
Jul 15, 2020, 14:25 ET
Share this article
NEW YORK, July 15, 2020 /PRNewswire/ -- Dr. Vladimir Zelenko, a New York based primary care physician, announced that a retrospective analysis based on his patient data is available to read online at
www.thezelenkoprotocol.com. The study, which has been submitted for peer review, found that early intervention and treatment of risk stratified COVID-19 patients in the outpatient setting resulted in five times less hospitalizations and deaths. The medications used in the treatment approach were zinc, low dose hydroxychloroquine, and azithromycin.
Prior studies of COVID-19 treatments have been largely based on severely ill patients in the hospital. This study examines outcomes of patients treated after their first visit to the doctor's office. Using simple risk stratification criteria, Dr. Zelenko identified which patients required prescriptions for the triple drug therapy, and prescribed these medications for five days.
To produce the study, Zelenko collaborated with Dr. Roland Derwand, a German medical doctor and life science industry expert, and Professor Martin Scholz, an independent consultant and adjunct professor for experimental medicine at Heinrich Heine University, Düsseldorf, Germany. Derwand and Scholz performed the data analysis while Zelenko handled all in-person treatments.
The main results show that of 141 patients who were treated with the triple therapy, only 2.8% (4/141) were hospitalized compared to 15.4% of an untreated control group (58/377) (odds ratio 0.16, 95% CI 0.06-0.5; p<0.001). Only 0.71% (1/141) patients died in the treatment group, versus 3.5% (13/377) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.16).
"These three medications are affordable, available in pill form, and work in synergy against COVID-19," said Zelenko. "Hydroxychloroquine's main function within this treatment approach is to allow zinc to enter the cell. Zinc is the virus killer, and azithromycin prevents secondary bacterial infection in the lungs and reduces the risk of pulmonary complications."
"The world seems to have forgotten common medical knowledge: that we want to treat any patient with an infectious disease as soon as possible," said Derwand. "What differentiates this study is that patients were prescribed these medications early, in the outpatient setting. Dr. Zelenko treated his risk stratified patients immediately and didn't wait for the disease to intensify."
"The well-tolerated 5-day triple therapy resulted in a significantly lower hospitalization rate and less fatalities with no reported cardiac side effects compared with relevant public reference data of untreated patients," said Sholz. "The magnitude of the results can substantially elevate the relevance of early use, low dose hydroxychloroquine, especially in combination with zinc. This data can be used to inform ongoing pandemic response policies as well as future clinical trials."
"It's unfortunate much of the news coverage surrounding hydroxychloroquine has been negative," Zelenko added. "This study suggests that when taken early and together with zinc and azithromycin, this cost-effective drug can be part of the solution to the pandemic."
CONTACT: countermediarelations@gmail.com
SOURCE Dr. Zev Zelenko
Related Links
Here is the peer reviewed study:
https://www.sciencedirect.com/science/article/pii/S0924857920304258(pre-print
July 3, 2020 https://www.preprints.org/manuscript/202007.0025/v1 )
https://www.thezelenkoprotocol.com/______________________
[Edit add 10-24-2023]
[end edit
